Robins Kaplan LLP is pleased to announce that Jake Holdreith has been named the 2019 Minnesota Outstanding IP Litigator by Managing Intellectual Property.
The award is based on research conducted for the 2019 edition of IP Stars, a guide to IP firms and practitioners worldwide. Holdreith was selected from a shortlist of five Minnesota lawyers who were chosen based on nominations sent by firms contacted for IP Stars research, as well as interview notes, survey submissions, and Managing Intellectual Property’s own independent research.
Holdreith leads Robin Kaplan’s Health and Life Sciences Industry Group and is well-known as strategist, trusted counselor and able courtroom lawyer. Over the course of his career, Holdreith has established himself as an innovative go-to patent litigator for generic pharmaceutical makers and technology companies alike. Jake has obtained multiple jury verdicts for patent owners ranging from $3 million to in excess of $34 million, as well as multiple defense judgments. In 2016 he represented Collegium in obtaining judgment of invalidity of three asserted patents that resulted in lifting a stay of FDA approval and permitted the launch of XTAMPZA, an abuse deterrent pain medication. Most recently, in July 2018, he and the Robins Kaplan team secured a rare ruling of non-infringement of a proposed ANDA product in a Hatch-Waxman trial over the blockbuster kidney disease drug Sensipar®.
As a leading attorney in the IP arena, Jake has been recognized by numerous publications for his outstanding work. He is ranked in IAM1000: The World’s Leading Patent Practitioners, has been named Minneapolis’ Intellectual Property Lawyer of the Year by Best Lawyers, a Life Sciences Star by LMG Life Sciences, a Patent and Trademark Star by Managing Intellectual Property, and in 2017 was recognized as an Intellectual Property Trailblazer by The National Law Journal.
Related Attorneys
Partner
